BRUSSELS (Reuters) – The European Commission said on Thursday it had concluded exploratory talks with CureVac regarding the purchase of 225 million doses of the German biotech firm’s potential COVID-19 vaccine.
“Today we concluded talks with the European company CureVac to increase the chances of finding an effective coronavirus vaccine,” EU Health Commissioner Stella Kyriakides said.
The EU will now begin talks on a contract with CureVac aimed at securing the supply of its potential vaccine for all 27 EU member states should the shot prove safe and effective against COVID-19.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.